Pfizer Inc. (NYSE:PFE – Get Free Report)’s stock price traded down 2.4% during mid-day trading on Tuesday . The stock traded as low as $27.72 and last traded at $27.78. Approximately 31,717,839 shares changed hands during mid-day trading, a decline of 24% from the average daily volume of 41,495,664 shares. The stock had previously closed at $28.45.
More Pfizer News
Here are the key news stories impacting Pfizer this week:
- Positive Sentiment: Pfizer’s recent rebound was supported by a quarterly earnings report that exceeded analyst expectations on both earnings and revenue, helping restore confidence in the beaten-down pharmaceutical stock. Why Pfizer Stock Was so Healthy in August
- Positive Sentiment: Commentary remains constructive on Pfizer’s approximately 6% dividend yield and the possibility that a strengthening drug pipeline could provide upside beyond income. One analyst cited a $32.72 12-month price target, implying potential appreciation from recent levels. Forget the Dividend: This Could Be the Real Reason to Buy Pfizer Stock Now
- Positive Sentiment: Novartis India agreed to acquire Pfizer brands for $132 million, including an established hypertension treatment. The transaction could provide cash and further streamline Pfizer’s portfolio toward higher-priority products, although its overall financial impact appears limited relative to Pfizer’s size. Novartis India Acquires Pfizer Brands for $132 Million
- Neutral Sentiment: CEO Albert Bourla is scheduled to discuss Pfizer at Morgan Stanley’s Global Healthcare Conference on September 14. Investors may look for updates on the pipeline, strategy, and outlook, but no new operating information was provided in the announcement. Pfizer Invites Public to Listen to Webcast
- Negative Sentiment: Pfizer’s high yield is attracting attention, but investors are being encouraged to choose AbbVie instead because of its stronger dividend-growth profile. This reinforces concerns that Pfizer may offer income today without comparable long-term dividend growth. Move Aside, Pfizer: This Stock Is the Smarter Dividend Buy Right Now
- Negative Sentiment: Broader commentary describes Pfizer as still struggling and highlights uncertainty surrounding its post-COVID growth strategy and next-generation drug pipeline. These concerns can limit investor enthusiasm despite the earnings beat and attractive valuation. This Is What I’d Do With Pfizer Stock Right Now
Analysts Set New Price Targets
A number of equities analysts have recently weighed in on the stock. Wolfe Research reaffirmed an “underperform” rating and set a $26.00 price target on shares of Pfizer in a research note on Thursday, May 14th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $27.00 price objective on shares of Pfizer in a research note on Monday, July 6th. Bank of America decreased their price objective on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. Guggenheim lowered their target price on shares of Pfizer from $35.00 to $31.00 and set a “buy” rating on the stock in a research report on Friday, August 7th. Finally, Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Saturday. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Pfizer currently has an average rating of “Hold” and a consensus price target of $28.28.
Pfizer Price Performance
The company has a 50-day moving average of $26.06 and a two-hundred day moving average of $26.34. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96. The stock has a market capitalization of $158.34 billion, a PE ratio of 36.55, a P/E/G ratio of 1.91 and a beta of 0.34.
Pfizer (NYSE:PFE – Get Free Report) last issued its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, topping the consensus estimate of $0.68 by $0.09. The business had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The business’s quarterly revenue was up 2.6% on a year-over-year basis. During the same period last year, the company posted $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Sell-side analysts predict that Pfizer Inc. will post 2.98 EPS for the current fiscal year.
Pfizer Dividend Announcement
The company also recently announced a quarterly dividend, which was paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th were paid a $0.43 dividend. The ex-dividend date was Friday, July 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.2%. Pfizer’s dividend payout ratio is 226.32%.
Institutional Trading of Pfizer
Hedge funds have recently made changes to their positions in the stock. Godfrey Financial Associates Inc. acquired a new position in Pfizer during the 4th quarter worth $26,000. Keb Asset Management LLC bought a new position in shares of Pfizer during the second quarter valued at approximately $26,000. Field & Main Bank acquired a new stake in Pfizer in the second quarter worth $27,000. HFM Investment Advisors LLC lifted its position in Pfizer by 61.0% in the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 427 shares during the last quarter. Finally, Evolution Wealth Management Inc. raised its holdings in shares of Pfizer by 132.2% during the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 566 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.
About Pfizer
Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.
Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.
Featured Stories
- Five stocks we like better than Pfizer
- Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected
- Despite Post-Earnings Drop, Wall Street Analysts Eye New Highs for Broadcom Stock
- Morgan Stanley Eyes Good Things Ahead for Meta After $18 Billion Legal Settlement
- Q3 Earnings Could Be the Catalyst the Market Has Been Waiting For
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
